The present findings suggest that the role of irisin as a protective myo‐adipokine in atypical metabolic situations needs further examination, but provides promising support for the potential pharmacotherapeutic use of irisin in the treatment of obesity and type 2 diabetes. Here, FNDC5 is linked to obesity disorder.